您的位置: 首页 > 农业专利 > 详情页

MODULATION OF PCSK9 AND LDLR THROUGH DRP1 INHIBITION
专利权人:
THE BRIGHAM AND WOMEN'S HOSPITAL; INC.
发明人:
Elena AIKAWA,Maximillian ROGERS,Masanori AIKAWA
申请号:
US16333460
公开号:
US20190209603A1
申请日:
2017.09.12
申请国别(地区):
US
年份:
2019
代理人:
摘要:
Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充